Blood-Based Biomarkers in Neurology: Harnessing the Potential of Neurofilament Light Chain in Relapsing Multiple Sclerosis

The landscape of neurology biomarkers has evolved significantly in recent years, affording new clinical insights that are helping to reshape patient care. During an expert interview conducted by the European Medical Journal (EMJ), Simon Thebault, Assistant Professor at Montreal Neurological Institute, and attending physician at McGill University Health Centre, Canada, explored important advancements in blood-based neurology biomarkers, focusing on the key role of neurofilament light chain (NfL). NfL is a neurone-specific protein and biomarker of axonal damage that can provide novel insights into disease activity in multiple sclerosis (MS) and aid in prognostication. New innovations in blood-based testing for NfL are helping to facilitate the clinical application of this key biomarker to improve MS disease management.